Helix Biopharma Corp. Initiates Enrollment for Fifth Cohort in Polish Phase I/II Clinical Study of its Lung Cancer Drug Candidate L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the fifth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle …

Helix BioPharma Corp. to Conduct Interim Review of its LDOS002 Phase I/II Clinical Study

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the treatment of cancer, today announced that it has completed patient enrolment in the fourth cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 and will perform an interim review of data collected for all subjects enrolled to …

Helix BioPharma Corp. Establishes Polish Subsidiary

(Aurora, Ontario) – Helix BioPharma Corp. (“Helix”) (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has established a Polish subsidiary (“Helix Polska”). Helix Polska was established to facilitate and support ongoing clinical oncology research at leading research institutions in Poland.

HELIX BIOPHARMA CORP. ANNOUNCES EXTENSION OF 2010 WARRANT EXPIRY DATE

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of the 2010 Warrants (as defined below) by eighteen months, from August 5, 2013 at 5:00 p.m. (Toronto time) (the …

HELIX BIOPHARMA ANNOUNCES CHANGE OF AUDITOR

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (the “Company” or “Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has initiated the process of changing Helix’s auditor from KPMG LLP (“KPMG”) to BDO Canada LLP (“BDO”). The change will be effective as of the completion of the audit for …

HELIX BIOPHARMA ANNOUNCES APPOINTMENT OF DIRECTOR

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Stace Wills to the board of directors. Mr. Wills is a resident Canadian and his appointment was effective June 12, 2013. Commenting on the appointment, Mario Gobbo, Chairman of the Board of Helix, …

HELIX BIOPHARMA CORP. INITIATES ENROLLMENT FOR FOURTH COHORT IN POLISH PHASE I/II CLINICAL STUDY OF ITS LUNG CANCER DRUG CANDIDATE L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the fourth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle …

Helix BioPharma Corp. announces L-DOS47 scientific poster to be presented at American Association for Cancer Research Annual Meeting in Washington, DC

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that Helix’s Chief Science Officer, Dr. Heman Chao, will be presenting a scientific poster at American Association for Cancer Research (AACR) Annual Meeting in Washington, DC on Tuesday April 9, 2013. Dr. Chao’s poster, entitled, Development …